Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)
Sponsor: Dermatologic Cooperative Oncology Group
A PHASE3 clinical study on Melanoma, this trial is completed. The trial is conducted by Dermatologic Cooperative Oncology Group and has accumulated 7 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
May 2017 — Jun 2017 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dermatologic Cooperative Oncology Group
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .